A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2002
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001091798A3 Tumor activated prodrug compounds
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	WO2001045577A9 Intervertebral disc treatment devices and methods
12/05/2002	WO2001024775A9 Gel-forming compositions
12/05/2002	WO2001019408A9 Nucleic acids encoding polyepitope polypeptides
12/05/2002	US20020183764 Embolic materials
12/05/2002	US20020183512 Compounds for use in treatment of cancer
12/05/2002	US20020183398 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
12/05/2002	US20020183394 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
12/05/2002	US20020183392 Inhibiting oxidative degradation of pharmaceutical formulations
12/05/2002	US20020183380 Administering anti-microtubule compound-containing, pharmaceutically acceptable formulation wherein anti-microtubule compound is paclitaxel for therapy and prophylaxis of surgical adhesions
12/05/2002	US20020183359 Ophthalmic composition
12/05/2002	US20020183296 Applying a hydroalcoholic gel containing testosterone to skin of the male subject in an amount effective to treat the hypogonadism
12/05/2002	US20020183293 Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage
12/05/2002	US20020183280 For controlled administration of pharmaceutically active agents to patients, wherein formulation is administered as liquids which thicken to form gels upon instillation into the eye
12/05/2002	US20020183265 Manufacture and use of an antibiotic/antibiotics preparation
12/05/2002	US20020183259 Terminally-branched polymeric linkers and polymeric conjugates containing the same
12/05/2002	US20020183257 PEG-LHRH analog conjugates
12/05/2002	US20020183256 Cytostatic-integrin conjugates having specifically cleavable linking units
12/05/2002	US20020183253 Effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with ocular neovascularization to an ocular neovascularization inhibiting effective amount
12/05/2002	US20020183248 Locally administering to a cutaneous site at least one lectin capable of interfering with the infective capability of a pathogenic microorganism toward dermal tissue, in an amount effective to diminish infective capability microorganism
12/05/2002	US20020183243 Polyglutamic acid-camptothecin conjugates and methods of preparation
12/05/2002	US20020182705 Method for increasing the serum half-life of a biologically active molecule
12/05/2002	US20020182659 Method to determine TGF-beta
12/05/2002	US20020182643 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182255 Especially a sustained release composition for the treatment of ocular and periocular infections.
12/05/2002	US20020182254 Biodegradable blend of polycaprolactone and crystallization modifier composed of a crystalline fatty acid or crystalline fatty acid ester of polyhydric alcohol for use in the controlled release of biologically active proteins
12/05/2002	US20020182253 Sustained-release microgranules containing diltiazem as active principle
12/05/2002	US20020182251 Antibiotic(s) preparation with retarding active ingredient release
12/05/2002	US20020182249 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
12/05/2002	US20020182247 Patches containing buprenorphine hydrochloride
12/05/2002	US20020182242 Especially for enhancing the repair of damaged or diseased bone and cartilage tissues.
12/05/2002	US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents
12/05/2002	US20020182205 Administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.
12/05/2002	US20020182190 Microparticle protection of therapeutic agents
12/05/2002	US20020182185 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
12/05/2002	US20020182172 A water soluble and non-peptidic polymer backbone covalently attached to a non-heteroatom position of a triazine derivative comprising a triazine ring
12/05/2002	US20020182155 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same
12/05/2002	US20020182146 Preparation of protein microspheres, films and coatings
12/05/2002	DE10221863A1 Phospholipidische Zusammensetzung sowie deren Verwendung Phospholipid composition and use thereof
12/05/2002	DE10126924A1 Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability
12/05/2002	DE10126253A1 Neuartig konfektionierte quaternäre Ammoniumverbindungen New made-quaternary ammonium compounds
12/05/2002	DE10126163A1 Solid, semi-solid or liquid pharmaceutical or cosmetic preparations, containing pyrogenic silicon dioxide of high tamped density as auxiliary to provide good flow properties
12/05/2002	DE10124820A1 Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut Composition and use of substances for the stabilization of sulfur-containing amino acids in blood
12/05/2002	DE10118282A1 Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and tackifier resins, for medical uses
12/05/2002	CA2459176A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	CA2452154A1 Carbohydrate modifying agent and drinks containing the modifying agent
12/05/2002	CA2449009A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
12/05/2002	CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	CA2448891A1 Long lasting fusion peptide inhibitors for hiv infection
12/05/2002	CA2448638A1 Nucleotide compounds that block the bitter taste of oral compositions
12/05/2002	CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002	CA2448570A1 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
12/05/2002	CA2448438A1 Soft elastic capsules comprising ritonavir and/or lopinavir
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448345A1 Stable liquid formulations of antibodies
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448100A1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	CA2448081A1 Medicinal compositions
12/05/2002	CA2447693A1 Taste-masking of highly water-soluble drugs
12/05/2002	CA2447562A1 Pirenzepine ophthalmic gel
12/05/2002	CA2441113A1 Embolic devices capable of in-situ reinforcement
12/04/2002	EP1262555A1 Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells
12/04/2002	EP1262490A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF
12/04/2002	EP1262236A1 Method for producing alpha-alumina formed body
12/04/2002	EP1262186A1 Azalide antibiotic compositions
12/04/2002	EP1262185A1 Synergistic antibiotic compositions
12/04/2002	EP1262173A1 Oral intake solution comprising reduced water
12/04/2002	EP1262172A1 Liquid polymer composition for prevention and treatment of the oral cavity diseases
12/04/2002	EP1262171A1 Novelly formulated quaternary ammonium compositions
12/04/2002	EP1262105A1 Phospholipid composition and use thereof
12/04/2002	EP1261874A1 Specific monoclonal antibody against terbinafine
12/04/2002	EP1261646A1 Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof
12/04/2002	EP1261639A2 Chondromodulin-i related peptide
12/04/2002	EP1261622A2 Purified lh
12/04/2002	EP1261613A1 Gastro-specific prodrugs
12/04/2002	EP1261568A2 Generation and screening of a dynamic combinatorial library
12/04/2002	EP1261421A1 Skincare agents
12/04/2002	EP1261378A2 Biodegradable immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261377A2 Immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261376A1 Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
12/04/2002	EP1261375A2 Compositions with enhanced oral bioavailability
12/04/2002	EP1261371A1 Membrane estrogen receptor-directed therapy in breast cancer
12/04/2002	EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261359A2 An improved herbal composition having antiallergic properties and a process for the preparation thereof
12/04/2002	EP1261355A1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
12/04/2002	EP1261351A2 Nystatin formulation having reduced toxicity
12/04/2002	EP1261347A1 Therapeutic compositions and methods for treatingperiodontitis with antiinflamatory compounds
12/04/2002	EP1261346A1 Modulation of cardiovascular injury
12/04/2002	EP1261340A2 Compositions and methods for the treatment of parkinson's disease
12/04/2002	EP1261337A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
12/04/2002	EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	EP1261319A1 Lipid carrier

1 ... 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 ... 1712